Abstract：
Unravel the regulatory mechanism of lncRNA CCDC144NL-AS1 in CRC hsa-miR-143-3p, downstream protein HMGA2 interaction arm, association with clinicopathological characteristics. Using peripheral blood as liquid biopsy from 60 CRC patients and 30 controls. The expression levels of CCDC144NL-AS1 and hsa-miR-143-3p detected by qRT-PCR. CCDC144NL-AS1 expression was significantly upregulated in CRC patients\' sera, associated with worse CRC clinicopathological features regarding the depth of tumor invasion and highly significant difference between tumor stages 3 and 4 and tumor stages 2 and 4. While, hsa-miR-143-3p expression was downregulated in CRC patients by 4.5-fold change when compared to the control subjects (p < 0.0001) and HMGA2 increased in CRC patients than controls 19.59 ng/μL and 5.377 ng/μL, respectively (p < 0.0001) with significant difference between tumor stages 3 and 4 as well as tumor stages 2 and 4. CRC patients with large tumor size showed upregulation in CCDC144NL-AS1 expression and HMGA2 levels compared to those with small tumor size (p-value = 0.0365 and 0.013, respectively). CCDC144NL-AS1 and HMGA2 were positively correlated, whereas lncRNA CCDC144NL-AS1 and hsa-miR-143-3p were negatively correlated. Conclusion: As an interaction arm CCDC144NL-AS1/hsa-miR-143-3p/HMGA2 were correlated to CRC stages 2-4. Therefore, this interaction arm expression clinically and in silico approved, would direct treatment precision in the near future.
摘要：
揭示lncRNACCDC144NL-AS1在CRC中的调控机制hsa-miR-143-3p,下游蛋白HMGA2相互作用臂，与临床病理特征相关。使用60例CRC患者和30例对照的外周血作为液体活检。qRT-PCR检测CCDC144NL-AS1和hsa-miR-143-3p的表达水平。CCDC144NL-AS1表达在CRC患者血清中显著上调,与更差的CRC临床病理特征有关的肿瘤浸润深度以及肿瘤3期和4期与2期和4期之间的高度显著差异相关。同时,与对照组相比，CRC患者的hsa-miR-143-3p表达下调4.5倍（p<0.0001），CRC患者的HMGA2比对照组19.59ng/μL和5.377ng/μL增加，（p<0.0001），肿瘤3期和4期以及肿瘤2期和4期之间存在显着差异。与肿瘤大小较小的CRC患者相比，肿瘤大小较大的CRC患者显示CCDC144NL-AS1表达和HMGA2水平上调（p值分别为0.0365和0.013）。CCDC144NL-AS1与HMGA2呈正相关,而lncRNACCDC144NL-AS1和hsa-miR-143-3p呈负相关。结论:作为相互作用臂,CCDC144NL-AS1/hsa-miR-143-3p/HMGA2与CRC阶段2-4相关。因此,这种相互作用臂表达在临床和计算机上获得批准，将在不久的将来指导治疗精度。
